CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
exendin(9-39)amide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00468091
NCT00468091Phase 1Completed
CompareCT.gov

Regulation of Antro-pyloro-duodenal and Proximal Gastric Motility by GLP-1: Involvement of Cholinergic Pathways

Ludwig-Maximilians - University of Munich·interventional·Posted May 1, 2007·Updated Apr 1, 2015

In Brief

A Phase 1 clinical trial evaluating exendin(9-39)amide and atropine for Digestive Physiology and 4 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study in humans is to define the effects of the endogenous hormone GLP-1 on gastroduodenal motility and on endocrine pancreatic secretion by using the specific GLP-1 receptor antagonist exendin(9-39). To elucidate possible cholinergic pathways, we combined exendin(9-39) with the muscarinergic antagonist atropine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDigestive Physiology, Gastrointestinal Motility, Gastrointestinal Hormones, Glucagon-like Peptide 1, Exendin (9-39)
CountriesGermany
CollaboratorsGerman Research Foundation, Philipps University Marburg

Timeline

Phase 1CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 1, 2007
Enrollment StartFeb 1, 1999
Study CompletionSep 1, 2000
TodayJul 2, 2026
Posted 19.2 years ago

Interventions

exendin(9-39)amidedrug

atropinedrug